Further, deeper insight into the role of ncRNA and associated signaling pathways in the SGLT2-i-induced processes in the T2DM models in vivo and cellular models in vitro should close this gap and enforce clinical application of ncRNA-based therapeutics. Here, SLC5A2 is linked to type 2 diabetes mellitus.